SNPs
POTENTIAL TARGETS FOR IMPROVING MEMORY AND COGNITION
The endocannabinoid system plays an important role in learning and memory, as well as the endocrine and immune systems.
Previous research has found that drugs that target cannabinoid receptor type-1 (CB1R) have the potential to treat neurological
disorders, such as Alzheimer's disease and epilepsy. Researchers from Universitat Pompeu Fabra Barcelona recently found that
such medications show promise in improving memory and cognition in Down syndrome. Using two types of Down syndrome
mouse models, they learned that CB1R inhibitors not only restored memory deficits and improved cognitive performance, but
also boosted synaptic plasticity (which influences how memories are stored and created) and neurogenesis (the growth of new
neurons) in the mice.
Navarro-Romero, et. al. Neurobiology of Disease, Jan. 2019 (e-pub); 125:92-106
CORRECTING VISION PROBLEMS EARLY IN LIFE
Children with Down syndrome frequently experience vision problems, but there is little consensus among eye health practitioners
about when parents should first have their children with Down syndrome evaluated. In this small study, Italian researchers had 42
children with Down syndrome undergo two forms of vision testing. One test, the Early Neurovisual Assessment, was conducted
at 6, 12, and 18 months of age, and the second, the Pediatric Ophthalmological Examination, at 36 months. Their results suggest
that administering the Early Neurovisual Assessment at 18 months was an optimal tool for identifying and addressing vision
problems early enough to allow for proper neurodevelopment.
Purpura, et. al. Early Human Development, Feb. 2019 (e-pub); 131:21-28